RemeGen Co. Ltd. Class A
688331
株式のランク
#2414
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces,... RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
株価
$14.49
時価総額
$8.11B
変化（1日）
2.99%
変化（1年）
9.18%
国
CN
取引 RemeGen Co. Ltd. Class A (688331)
カテゴリー
Healthcare
RemeGen Co. Ltd. Class A（688331）の利益
Jun 2026 時点の利益 TTM: $843.65M
RemeGen Co. Ltd. Class A の最新の財務報告によると、同社の現在の利益は $843.65M です。2023 年には $-213.49M の利益を上げ、これは 2022 年の利益 $-144.80M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
RemeGen Co. Ltd. Class A の利益の推移（2018 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $843.65M | -519.37% |
| 2024 | $-201.17M | -5.77% |
| 2023 | $-213.49M | 47.44% |
| 2022 | $-144.80M | -433.15% |
| 2021 | $43.46M | -140.69% |
| 2020 | $-106.82M | 72.87% |
| 2019 | $-61.79M | 57.45% |
| 2018 | $-39.24M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $5.27B | 525.25% |
US
|
|
| $-3.09B | -465.91% |
US
|
|
| $-4.02B | -576.05% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 131.22% |
NL
|
